GlassScriptPhysician profile
James L Khatcheressian
NPI 1366536674
$22,960.86
in general payments reported to CMS, 2019-2025
30 companies · $3,672 in 2025
The $3,672 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.16 · 2020: $8,604 · 2021: $11.92 · 2022: $365 · 2023: $10K · 2024: $239 · 2025: $3,672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,296 · Food and Beverage: $2,443 · Travel and Lodging: $2,203 · Gift: $19.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,296.25 |
| Food and Beverage | $2,443.48 |
| Travel and Lodging | $2,203.46 |
| Gift | $19.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $18,425.86 | 2020-2023 | Enhertu |
| Onmark, INC. | $3,306.57 | 2025 | |
| Janssen Biotech, INC. | $208.78 | 2022-2025 | Darzalex, Tecvayli, Talvey |
| Novartis Pharmaceuticals Corporation | $139.38 | 2022-2025 | |
| Glaxosmithkline, LLC. | $119.84 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Pfizer INC. | $97.56 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $75.71 | 2022-2025 | Keytruda, Keytruda Qlex |
| Astellas Pharma US INC | $52.79 | 2022-2023 | Xtandi, Xospata |
| Eisai INC. | $49.75 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $42.60 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $40.80 | 2022-2025 | Onivyde |
| Astrazeneca Pharmaceuticals LP | $36.36 | 2019-2023 | Enhertu |
| Abbvie INC. | $35.65 | 2024 | |
| Gilead Sciences, INC. | $33.92 | 2021-2024 | |
| Cti Biopharma Corp. | $32.78 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.19 | 2022 | |
| Deciphera Pharmaceuticals INC. | $27.42 | 2025 | Qinlock, Romvimza |
| Seagen INC. | $26.22 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $26.09 | 2022-2023 | Imbruvica |
| Kite Pharma, INC. | $25.02 | 2023 | Yescarta |
| Stemline Therapeutics INC. | $23.44 | 2023 | Orserdu |
| E.R. Squibb & Sons, L.L.C. | $21.78 | 2025 | Opdivo |
| G1 Therapeutics, INC. | $20.83 | 2023 | Cosela |
| Incyte Corporation | $16.17 | 2022 | |
| Novocure INC. | $15.62 | 2024 | Optune |
| Taiho Oncology, INC. | $15.55 | 2022 | |
| Adc Therapeutics America, INC. | $13.18 | 2023 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Khatcheressian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.